Tivantinib
As of the edition of 20 October 2026, Tivantinib is a small molecule: went quiet in 2019; acts on MET.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2019
- Kind
- Small molecule
- Registered trials
- 45, 6 stopped early
- Disease areas
- Cancer; Lungs and airways; Digestive system; Urinary and reproductive; Pregnancy and women's health; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route A because of this drug.
Companies on route A for this drug
In the product3 companies are on route A because of Tivantinib.
See the 3 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MET | Hepatocyte growth factor receptor | P08581 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 20 | 20 | 0 | 0 |
| Phase 2 | 21 | 17 | 0 | 4 |
| Phase 3 | 4 | 2 | 0 | 2 |
| All trials | 45 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Daiichi Sankyo | Lead sponsor of trials | 2010 to now |
| Kyowa Kirin | Lead sponsor of trials | 2010 to now |
| Merck & Co. | Lead sponsor of trials | 2010 to now |
| SCRI Development Innovations | Lead sponsor of trials | 2012 to now |